A Randomized, Controlled Trial of Cannabis in Healthy Volunteers Evaluating Simulated Driving, Field Performance Tests and Cannabinoid Levels

INVESTIGATORS: Thomas Marcotte, Ph.D. & Barth Wilsey, M.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: A Randomized, Controlled Trial of Cannabis in Healthy Volunteers Evaluating Simulated Driving, Field Performance Tests and Cannabinoid Levels

PROJECT TYPE: Clinical Study

STATUS: ACTIVE

ABSTRACT:

This study was authorized by the California Legislature (Assembly Bill 266, the Medical Marijuana Regulation and Safety Act) to help with detection of driving under the influence of cannabis. Healthy volunteers will inhale smoked cannabis with either 0% (placebo), 6.7%, or 12.6% Δ9-THC at the beginning of the day, and then complete driving simulations, iPad-based performance assessments, and bodily fluid draws (e.g., blood, saliva, breath) before the cannabis smoking and hourly over the subsequent 7 hours after cannabis smoking. The purpose is to determine (1) the relationship of the dose of Δ9-THC on driving performance and (2) the duration of driving impairment in terms of hours from initial use, (3) if saliva or expired air can serve as a useful substitute for blood sampling of Δ9-THC in judicial hearings and (4) if testing using an iPad can serve as a useful adjunct to the standardized field sobriety test in identifying acute impairment from cannabis.

 

Interested in participating? Click here to contact us.

New Breathalyzer May Detect Pot Impairment

Megan Tevrizian, NBC7 San Diego, August 7, 2018

A California company may have developed a game changer for detecting impaired drivers.

The company Hound Labs created a breathalyzer able to detect the amount of THC in a driver's breath.

“It’s an incredibly challenging scientific problem to ensure the really, really low concentrations,” said Hound Labs CEO Mike Lynn.

“We’re talking parts per trillion in your breath,” Lynn said.

The device uses the breath to measure THC, the psychoactive chemical in pot that makes you high.

Read the story here


How One Boy's Fight With Epilepsy Led To The First Marijuana-Derived Pharmaceutical

Lesley McClurg, KQED, August 6, 2018

The first prescription medication extracted from the marijuana plant is poised to land on pharmacists' shelves this fall. Epidiolex, made from purified cannabidiol, or CBD, a compound found in the cannabis plant, is approved for two rare types of epilepsy.

Its journey to market was driven forward by one family's quest to find a treatment for their son's epilepsy.

Scientific and public interest in CBD had been percolating for several years before the Food and Drug Administration finally approved Epidiolex in June. But CBD — which doesn't cause the mind-altering high that comes from THC, the primary psychoactive component of marijuana — was hard to study, because of tight restrictions on using cannabis in research.

Read the article here


Landscape on marijuana research shifting despite federal roadblocks

Brooke Staggs, Orange County Register, August 1, 2018

The legalization of recreational cannabis raises new opportunities, and challenges, in addressing the health and safety effects of cannabis use.

After decades of disconnect between federal officials who consider cannabis a harmful drug and public opinion that increasingly views cannabis as something that should be legal and is potentially good medicine, the landscape on marijuana research might be shifting.

This week, UC Irvine announced it received a $9 million grant from the National Institute on Drug Abuse to study how long-term cannabis exposure affects young people’s brains.

California regulators also are setting up a process to award $10 million by summer 2019 — and $10 million more each year for the next decade — for universities to study the impacts of marijuana legalization.

And a bill recently proposed in Congress would apply the new California research model across the country, allowing scientists to gather data and study the effects of cannabis legalization nationwide for a decade.

Read the rest of the article here


More News

Click here to access the CMCR news archives.

Igor Grant, MD

Introduction/Overview
CMCR Symposium, June 2018


Daniele Piomelli, MD, PhD, PharmD

The health impact of cannabis
CMCR Symposium, June 2018


Ziva Cooper, PhD

Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018


Iain McGregor, PhD

Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018


Thomas Marcotte, PhD

Cannabis and public safety: The challenge of cannabis-impaired driving
CMCR Symposium, June 2018


Copyright © 2018 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego
cmcr@ucsd.edu | HNRP |